153 related articles for article (PubMed ID: 31589621)
1. A rapid, low pH, nutrient stress, assay to determine the bactericidal activity of compounds against non-replicating Mycobacterium tuberculosis.
Early JV; Mullen S; Parish T
PLoS One; 2019; 14(10):e0222970. PubMed ID: 31589621
[TBL] [Abstract][Full Text] [Related]
2. Determination of compound kill kinetics against Mycobacterium tuberculosis.
Early J; Alling T
Methods Mol Biol; 2015; 1285():269-79. PubMed ID: 25779322
[TBL] [Abstract][Full Text] [Related]
3. A class of hydrazones are active against non-replicating Mycobacterium tuberculosis.
Bonnett SA; Dennison D; Files M; Bajpai A; Parish T
PLoS One; 2018; 13(10):e0198059. PubMed ID: 30332412
[TBL] [Abstract][Full Text] [Related]
4. A luciferase-based assay for rapid assessment of drug activity against Mycobacterium tuberculosis including monitoring of macrophage viability.
Larsson MC; Lerm M; Ängeby K; Nordvall M; Juréen P; Schön T
J Microbiol Methods; 2014 Nov; 106():146-150. PubMed ID: 25194234
[TBL] [Abstract][Full Text] [Related]
5. InhA inhibitors have activity against non-replicating Mycobacterium tuberculosis.
Flint L; Korkegian A; Parish T
PLoS One; 2020; 15(11):e0239354. PubMed ID: 33201882
[TBL] [Abstract][Full Text] [Related]
6. Rapid, Semiquantitative Assay To Discriminate among Compounds with Activity against Replicating or Nonreplicating Mycobacterium tuberculosis.
Gold B; Roberts J; Ling Y; Quezada LL; Glasheen J; Ballinger E; Somersan-Karakaya S; Warrier T; Warren JD; Nathan C
Antimicrob Agents Chemother; 2015 Oct; 59(10):6521-38. PubMed ID: 26239979
[TBL] [Abstract][Full Text] [Related]
7. Killing of non-replicating Mycobacterium tuberculosis by 8-hydroxyquinoline.
Darby CM; Nathan CF
J Antimicrob Chemother; 2010 Jul; 65(7):1424-7. PubMed ID: 20435781
[TBL] [Abstract][Full Text] [Related]
8. Identification of Compounds with pH-Dependent Bactericidal Activity against Mycobacterium tuberculosis.
Early J; Ollinger J; Darby C; Alling T; Mullen S; Casey A; Gold B; Ochoada J; Wiernicki T; Masquelin T; Nathan C; Hipskind PA; Parish T
ACS Infect Dis; 2019 Feb; 5(2):272-280. PubMed ID: 30501173
[TBL] [Abstract][Full Text] [Related]
9. A dual read-out assay to evaluate the potency of compounds active against Mycobacterium tuberculosis.
Ollinger J; Bailey MA; Moraski GC; Casey A; Florio S; Alling T; Miller MJ; Parish T
PLoS One; 2013; 8(4):e60531. PubMed ID: 23593234
[TBL] [Abstract][Full Text] [Related]
10. Activity of rifampicin and linezolid combination in Mycobacterium tuberculosis.
Maltempe FG; Caleffi-Ferracioli KR; do Amaral RCR; de Oliveira Demitto F; Siqueira VLD; de Lima Scodro RB; Hirata MH; Pavan FR; Cardoso RF
Tuberculosis (Edinb); 2017 May; 104():24-29. PubMed ID: 28454646
[TBL] [Abstract][Full Text] [Related]
11. The role of the time-kill kinetics assay as part of a preclinical modeling framework for assessing the activity of anti-tuberculosis drugs.
Bax HI; Bakker-Woudenberg IAJM; de Vogel CP; van der Meijden A; Verbon A; de Steenwinkel JEM
Tuberculosis (Edinb); 2017 Jul; 105():80-85. PubMed ID: 28610791
[TBL] [Abstract][Full Text] [Related]
12. Differential drug susceptibility of intracellular and extracellular tuberculosis, and the impact of P-glycoprotein.
Hartkoorn RC; Chandler B; Owen A; Ward SA; Bertel Squire S; Back DJ; Khoo SH
Tuberculosis (Edinb); 2007 May; 87(3):248-55. PubMed ID: 17258938
[TBL] [Abstract][Full Text] [Related]
13. A multi-stress model for high throughput screening against non-replicating Mycobacterium tuberculosis.
Gold B; Warrier T; Nathan C
Methods Mol Biol; 2015; 1285():293-315. PubMed ID: 25779324
[TBL] [Abstract][Full Text] [Related]
14. In vitro activity of C-8-methoxy fluoroquinolones against mycobacteria when combined with anti-tuberculosis agents.
Lu T; Drlica K
J Antimicrob Chemother; 2003 Dec; 52(6):1025-8. PubMed ID: 14613961
[TBL] [Abstract][Full Text] [Related]
15. Activity of trifluoperazine against replicating, non-replicating and drug resistant M. tuberculosis.
Advani MJ; Siddiqui I; Sharma P; Reddy H
PLoS One; 2012; 7(8):e44245. PubMed ID: 22952939
[TBL] [Abstract][Full Text] [Related]
16. Identification of a novel inhibitor of isocitrate lyase as a potent antitubercular agent against both active and non-replicating Mycobacterium tuberculosis.
Liu Y; Zhou S; Deng Q; Li X; Meng J; Guan Y; Li C; Xiao C
Tuberculosis (Edinb); 2016 Mar; 97():38-46. PubMed ID: 26980494
[TBL] [Abstract][Full Text] [Related]
17. Bactericidal activity of 2-nitroimidazole against the active replicating stage of Mycobacterium bovis BCG and Mycobacterium tuberculosis with intracellular efficacy in THP-1 macrophages.
Khan A; Sarkar S; Sarkar D
Int J Antimicrob Agents; 2008 Jul; 32(1):40-5. PubMed ID: 18538548
[TBL] [Abstract][Full Text] [Related]
18. Enhancement of in vitro activity of tuberculosis drugs by addition of thioridazine is not reflected by improved in vivo therapeutic efficacy.
de Knegt GJ; ten Kate MT; van Soolingen D; Aarnoutse R; Boeree MJ; Bakker-Woudenberg IA; de Steenwinkel JE
Tuberculosis (Edinb); 2014 Dec; 94(6):701-7. PubMed ID: 25621361
[TBL] [Abstract][Full Text] [Related]
19. Microplate Alamar Blue Assay (MABA) and Low Oxygen Recovery Assay (LORA) for Mycobacterium tuberculosis.
Cho S; Lee HS; Franzblau S
Methods Mol Biol; 2015; 1285():281-92. PubMed ID: 25779323
[TBL] [Abstract][Full Text] [Related]
20. Bioluminescence for assessing drug potency against nonreplicating Mycobacterium tuberculosis.
Vocat A; Hartkoorn RC; Lechartier B; Zhang M; Dhar N; Cole ST; Sala C
Antimicrob Agents Chemother; 2015 Jul; 59(7):4012-9. PubMed ID: 25896710
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
